Marianna Koczywas
City Of Hope National Medical Center · 204 works · 8,012 citations · h-index 45
Top works
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
- Small Cell Lung Cancer
- Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma
- Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer
- Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- Palliative Care in Lung Cancer
- Interdisciplinary Palliative Care for Patients With Lung Cancer
- NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
- Effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer
- Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial
- First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
- A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib
- Overcoming Barriers to Cancer Pain Management: An Institutional Change Model
- Defining a standard set of patient-centred outcomes for lung cancer
- Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
- New Standards and Implications for Improving the Quality of Supportive Oncology Practice
- Barriers to pain assessment and management in cancer survivorship